Results 251 to 260 of about 69,008 (285)

Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab

Signal Transduction and Targeted Therapy, 2021
Weimiao Li, An-Gang Yang, Lin-Tao Jia
exaly  

Trastuzumab

Reactions Weekly, 2023
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2020
  +4 more sources

Trastuzumab

Reactions Weekly, 2021
openaire   +2 more sources

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2017
openaire   +1 more source

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Nature Reviews Clinical Oncology, 2021
Yoshiaki Nakamura, Florian Lordick, Yelena Y Janjigian   +2 more
exaly  

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2018
openaire   +1 more source

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Journal of Clinical Oncology, 2020
Nancy U Lin, Virginia F Borges, Carey K Anders   +2 more
exaly  

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Lancet Oncology, The, 2020
Sandra M Swain, Martina Uttenreuther-Fischer, Young-Hyuck Im   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2013
openaire   +2 more sources